BIOGEN INC. - COMMON STOCK

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

17 أبريل 2024 09:50:10 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

16 أبريل 2024 09:45:06 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

15 أبريل 2024 09:45:35 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

12 أبريل 2024 12:00:50 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

10 أبريل 2024 09:45:08 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

05 أبريل 2024 09:45:10 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 أبريل 2024 09:53:33 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

03 أبريل 2024 09:55:31 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

02 أبريل 2024 09:45:41 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 أبريل 2024 10:34:07 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

26 مارس 2024 09:50:02 بحسب NetDania Notify

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

06 مارس 2024 07:30:51 بحسب Nasdaq GlobeNewswire

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

04 مارس 2024 16:15:57 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 مارس 2024 09:47:17 بحسب NetDania Notify

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

23 فبراير 2024 07:00:26 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

20 فبراير 2024 09:45:15 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

16 فبراير 2024 09:48:44 بحسب NetDania Notify

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

12 فبراير 2024 16:06:00 بحسب Nasdaq GlobeNewswire

Biogen to Realign Resources for Alzheimer's Disease Franchise

31 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

19 ديسمبر 2023 07:30:21 بحسب Nasdaq GlobeNewswire